COVID-19 RESOURCES

Refer to this page for the latest educational resources and information on lenzilumab as a therapeutic for cytokine storm resulting from COVID-19 infection.

For information on Humanigen's Phase 3 Clinical Trial visit ClinicalTrials.gov (Identifier: NCT04351152)

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19

March 29, 2021

Read the Full Press Release

Article | Clinical Trials Arena

Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated Covid-19 patients; mixed views on ideal timepoint to measure clinical improvements

Research Article | Science Immunology

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Article | Clinical Trials Arena

Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated Covid-19 patients

Preprint | medRxiv

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Article | Scientific American

The Coronavirus is Here to Stay—Here’s What That Means

Radio Interview | KISS 104.1 Atlanta

Humanigen's Dr. Cameron Durrant Joins KISS 104.1

Research | J Transl Med

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

Podcast | JAMA Network

COVID-19 Update—Critical Care and Pandemic Response

News | KXAN

Austin hospitals to help test new COVID-19 treatment

Perspective | NEJM

Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19

Article | BioCentury

Warp Speed’s Slaoui expects two COVID-19 vaccines this year

Article | Am J Respir Crit Care Med.

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

Article | BioWorld

Snowballing research preps avalanche to bury COVID-19

Preprint | medRxiv

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Interview | Proactive Investors

Humanigen CEO Discusses Phase III Trial for Lenzilumab in COVID-19 Patients

Article | The New York Times

The Coronavirus Patients Betrayed by Their Own Immune Systems

Graphic | Reuters

Ventilators: a bridge between life and death?

Research Letter | JAMA

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Preprint | IHME

Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths

Opinion | Bloomberg

Coronavirus: Why Surgeons Don't Want to Operate Right Now

Preprint | Cell Press

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Preprint | bioRxiv

GM-CSF and Cytokine Storm in Coronavirus

Research | JAMA Internal Medicine

Acute Respiratory Distress Syndrome and Death in Coronavirus Patients

Article | BioWorld

Humanigen preps lenzilumab for battle with COVID-19 symptom

Supplemental information | The Lancet

Data on immunology and inflammation in COVID-19

Article | The Atlantic

Why the Coronavirus Has Been So Successful

Review | American Society for Microbiology

Into the Eye of the Cytokine Storm

Article | Evaluate

Tiziana takes a deep breath and targets Covid-19

Preprint | medRxiv

Lung bronchoalveolar immune cells in COVID-19

Journal | The Lancet

COVID-19 RESOURCES

Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated Covid-19 patients; mixed views on ideal timepoint to measure clinical improvements

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated Covid-19 patients

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

The Coronavirus is Here to Stay—Here’s What That Means

Humanigen's Dr. Cameron Durrant Joins KISS 104.1

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

COVID-19 Update—Critical Care and Pandemic Response

Austin hospitals to help test new COVID-19 treatment

Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19

Warp Speed’s Slaoui expects two COVID-19 vaccines this year

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

Snowballing research preps avalanche to bury COVID-19

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Humanigen CEO Discusses Phase III Trial for Lenzilumab in COVID-19 Patients

The Coronavirus Patients Betrayed by Their Own Immune Systems

Ventilators: a bridge between life and death?

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths

Coronavirus: Why Surgeons Don't Want to Operate Right Now

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

GM-CSF and Cytokine Storm in Coronavirus

Acute Respiratory Distress Syndrome and Death in Coronavirus Patients

Humanigen preps lenzilumab for battle with COVID-19 symptom

Data on immunology and inflammation in COVID-19

Why the Coronavirus Has Been So Successful

Into the Eye of the Cytokine Storm

Tiziana takes a deep breath and targets Covid-19

Lung bronchoalveolar immune cells in COVID-19

Clinical features of coronavirus patients in Wuhan, China